KRAS G12C Inhibitor JNJ-74699157

**Semantic type:** Pharmacologic Substance

**Definition:** An orally available, small molecule inhibitor of the oncogenic Kirsten rat sarcoma virus homolog KRAS glycine-to-cysteine substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration JNJ-74699157 targets and binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

**Synonyms:** - ARS 3248 - ARS-3248 - ARS3248 - G12C Mutant KRAS Protein Inhibitor JNJ-74699157 - JNJ 74699157 - JNJ-74699157 - JNJ74699157 - KRASG12C Inhibitor JNJ-74699157